The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan versus investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor positive, HER2 negative breast cancer with disease progression following endocrine and CDK4/6 inhibitor therapy in either the adjuvant or first-line metastatic settings. Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being developed jointly by Daiichi Sankyo and Merck (MRK).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Market Wrap: U.S. Equities Slump to Start the Week, with the Dow Shedding 349 Points
- Merck & Co.’s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges
- Merck announces Breakthrough Therapy Designation for ifinatamab deruxtecan
- Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
- Trump Trade: Pharma tariff announcement likely ‘weeks away’